Corcept Therapeutics Incorporated (0I3Q.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 3.53B |
| Enterprise Value | 3.42B |
| P/E Ratio | 220.17 |
| PEG Ratio | -3.75 |
| Price/Sales Ratio | 14.9 |
| Price/Book Ratio | 17.09 |
| Enterprise/Revenue | 14.77 |
| Enterprise/EBITDA | 426.36 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
Profitability
| Profit Margin | 0.07 |
| Operating Margin | 0.01 |
AD
Management Effectiveness
| Return On Assets | 0.06 |
| Return On Equity | 0.08 |
Income Statement
| Revenue | 761.41M |
| Revenue/Share | 7.88 |
| Gross Profit | 748.43M |
| EBITDA | 46.69M |
| Net Income | 99.65M |
| Diluted EPS | 0.82 |
Balance Sheet
| Total Cash | 308.2M |
| Total Cash/Share | 2.92 |
| Total Debt | 9.42M |
| Total Debt/Equity | 0.01 |
| Current Ratio | 2.86 |
| Book Value Per Share | 6.7 |
Price History
| 52-Week Change | 60.94 |
| 52-Week High | 122.57 |
| 52-Week Low | 20.76 |
| Moving Average 50 Days | 23.44 |
| Moving Average 200 Days | 26 |
Statistics
| Average Volume | 2,318 |
| Shares Outstanding | 104.27M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
